This company is no longer active
AVROBIO (AVRO) Stock Overview
A clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AVRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AVROBIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.80 |
| 52 Week High | US$19.80 |
| 52 Week Low | US$10.56 |
| Beta | 1.22 |
| 1 Month Change | 1.45% |
| 3 Month Change | 9.38% |
| 1 Year Change | 44.82% |
| 3 Year Change | -85.45% |
| 5 Year Change | -90.89% |
| Change since IPO | -95.51% |
Recent News & Updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13
We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23
Shareholder Returns
| AVRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -0.2% | -0.5% |
| 1Y | 44.8% | 26.9% | 15.4% |
Return vs Industry: AVRO exceeded the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: AVRO exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| AVRO volatility | |
|---|---|
| AVRO Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVRO has not had significant price volatility in the past 3 months.
Volatility Over Time: AVRO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 13 | Erik Ostrowski | www.avrobio.com |
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company’s pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease.
AVROBIO, Inc. Fundamentals Summary
| AVRO fundamental statistics | |
|---|---|
| Market cap | US$63.75m |
| Earnings (TTM) | US$30.31m |
| Revenue (TTM) | n/a |
Is AVRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$30.31m |
| Earnings | US$30.31m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/20 12:10 |
| End of Day Share Price | 2024/06/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVROBIO, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yun Zhong | BTIG |
| Whitney Ijem | Guggenheim Securities, LLC |
| Debjit Chattopadhyay | H.C. Wainwright & Co. |